All News

Fracture%20bone.png (keep)

NY Times on Osteoporosis in Men

d Jack Cush, MD

The NY Times has addressed the problem of osteoporosis in men noting a need for increased awareness and screening. Takeaways:

Read Article
PSA2L.jpg

Gender Complexities in Psoriatic Arthritis Treatment Outcomes

d Jack Cush, MD

Analysis of a German psoriatic arthritis (PsA) patients registry demonstrates sex-specific differences regarding clinical manifestation and treatment outcomes, especially with regard to drug discontinuations.

Read Article
pill,pain,med,hand

Tramadol not effective at chronic pain

d EurekAlert!

The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published online in BMJ Evidence Based Medicine.

Read Article
op.compare.jpg

Osteoporosis Screening in High-Risk Men

d Jack Cush, MD

A Veterans Affairs (VA) Health Systems study of older male veterans found benefits of a remote model of screening that significantly improved osteoporosis screening, treatment, and adherence compared with usual care, with high patient and clinician acceptance.

Read Article
Stop%20Biologics%20green.png

Optimizing DMARD Therapy in Rheumatoid Arthritis

d Jack Cush, MD

A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare.

Read Article
RA Hands Difficult deformity

Not all difficult-to-treat RA will have rapid radiographic progression

d Jack Cush, MD

A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy.

Read Article
Systematic review of Still's Dz (240 articles, 95 sJIA, 134 AOSD, 23,136 pts); sJIA Dx by ILAR in 78% & AOSD used Yamaguchi criteria 98%. While clinical and lab findings were matched betw AOSD & sJIA, there was variability in MAS , outocmes & trajectory. Standarization needed

Dr. John Cush RheumNow ( View Tweet)

Optimizing DMARD Therapy in Rheumatoid Arthritis A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare. https://t.co/37O3mAulGy https://t.co/y7OkkzRZUg

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow is LIVE from #ACR25 Oct 24–29. KOL perspective videos, clinical-trial highlights, daily recaps & live streaming—all in one feed. https://t.co/pPwJNOyEFU
Dr. John Cush RheumNow ( View Tweet)
Associations in Rheumatology (10.3.2025) Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow. https://t.co/pnLoquR4By https://t.co/PKJuxMGrZy

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective study of 62 lupus nephritis pts rx w/ induction therapy - MMF vs IV CYC x 6 mos followed by MMF for next 6 mos. At 1 year complete renal remission (CRR) seen in 77% MMF vs 29% CYC. https://t.co/wG2Qrn1PSU https://t.co/gP8XYO4q92

Links:

Dr. John Cush RheumNow ( View Tweet)
Ethnic Minority Rheumatoid Arthritis Consortium registry study of 1315 RA pts (Dz duration 10yrs) incl 29% Blacks found Blacks in less remission(~2-fold by DAS28), more mod-hi dz activity, & frequently met active disease eligibility for RCTs. https://t.co/SfkVUB1GBz https://t.co/OwvmALHPFA

Links:

Dr. John Cush RheumNow ( View Tweet)
German survey of 124 AOSD pts - Dz duration 7 yrs (Dx delay 2 yrs), 2/3 on biologics, 84% responding, 81% inactive by CRP. MDs report 35% of pts Sx-free. More Patients report Persistent Sxs LBP (39.5%), fatigue/weakness (39%), & joint inflammation (27%). https://t.co/2FGUPrhB8H
Dr. John Cush RheumNow ( View Tweet)
Phase 3 RCT Cannabis sativa DKJ127 (VER-1) in 820 chronic low back pain (cLBP) pts. Primary endpt at wk 12 showed pain reduction of −1.9 NRS VER-01 vs −0.6 PBO (P < 0.001). Pain further decreased to −2.9 w/ 6 mos OL Rx. VER-1 was well tolerated. No addiction https://t.co/IeCV8tU2WR
Dr. John Cush RheumNow ( View Tweet)
Systematic review of obesity management meds - 56 RCTs (60,307 pts). All OMMs were better at total weight loss than PBO (P < 0.0001), >10% semaglutide & tirzepatide (both effective at NIDDM CHF). Semaglutide effective reducing pain in knee osteoarthritis https://t.co/nbdZfBDukE
Dr. John Cush RheumNow ( View Tweet)
ILD in Juvenile Dermatomyositis: Moving Toward Better Outcomes JDM is typically recognized for its striking skin rashes, vasculopathy, and muscle inflammation. Less visible, but equally significant, is lung involvement. ILD is increasingly acknowledged as a critical driver of https://t.co/vNGWAB88Mc
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Deuruxolitinib for use in adult patients with moderate to severe Alopecia Areata https://t.co/D6KXtDjfHL https://t.co/2WSIBWNexX

Links:

Dr. John Cush RheumNow ( View Tweet)
Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis FDA announced yesterday that guselkumab (Tremfya) is approved for use in pediatric patients moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA) in children six years and older https://t.co/GHjCgqHaJC
Dr. John Cush RheumNow ( View Tweet)
What is IPAF? Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD. https://t.co/ThU4pq27MU https://t.co/AOa5PALJst

Links:

Dr. John Cush RheumNow ( View Tweet)

🆕 ILD (Part III): clinical practice focus 🔬 Diagnostic challenges 🧑⚕️ Case-based learning 📈 Evidence & outcomes 🌍 Global perspectives ⬇️ Download & learn more: https://t.co/WhpVzAfPDD Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/4CL9mX9D6Y

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×